Drug manufacturer AstraZeneca, one of the first companies to place restrictions on 340B discounts in the contract pharmacy setting, has [...] …
Year: 2023
The 340B drug pricing program does not improve inpatient care quality for underserved patients, a recent government-funded analysis concluded. A [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
GlaxoSmithKline is sending 340B covered entities refunds for overcharges totaling $100 or more for purchases of two dosage forms of [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
While two drug manufacturers have recently relaxed or suspended their 340B contract pharmacy restrictions as a result of state laws [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The lead plaintiff in the legal battle that resulted in Medicare proposing an unusual lump sum payback for hospitals’ lost [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Congress should let for-profit hospitals into the 340B drug pricing program as “a long overdue evolutionary step” that will advance [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Drug makers AbbVie, Bristol Myers Squibb, Janssen, Lilly, and Merck asked a federal district court in South Carolina on Friday [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Changes in the ways Medicare calculates hospitals’ shares of low-income patients that were finalized in a recent payment rule will [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
SPONSORED CONTENT
Are you telling your 340B story? This webinar will teach you how to track the key data points that demonstrate the value of your 340B program. You will learn how to calculate your overall savings, track patient benefits, and create an Impact Profile.
…
The U.S. Government Accountability Office late last month restated its controversial recommendation that Congress take actions to reduce incentives for [...] …
